MARKET WIREYahoo • 15h ago
Regeneron: 3 Key Takeaways for Long-Term InvestorsAn early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
Why SNY Stock surged +2.11% Today — RQD Quant Desk Flash
$43.13 +2.11% NASDAQ • Public Delayed / 60s Snapshot
Sanofi ADS (SNY) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C • HOLD / WATCH
Cap $105.19B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
WHALE OPTIONS TUG-OF-WAR:56% Call Buyers ($10.7M)
44% PutsMax Pain: $42.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SNY Stock surged +2.11% Today — RQD Quant Desk Flash
Sanofi ADS (SNY) surged +2.11% to $43.13 as options desks priced 56% call premium vs. 44% put protection around the $42 max-pain magnet. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 30% of its 52-week range ($39.07 – $52.68) with RSI-14 at 68.4 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $10.7M in bullish call flow vs. $8.2M in put flow (Put/Call 0.77x, implied earnings swing ±7.4%).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 41% gross margin and $2.3B annual free cash flow.
Live SNY Headlines & Catalysts
CATALYSTYahoo • 16h ago
Regeneron Stock Just Hit a 2-Year High. Here's Why.Regeneron rallied to a two-year high as Dupixent drives strong Q3 earnings. But is there any further upside left in REGN shares? Let’s find out!
CATALYSTYahoo • 21h ago
Regeneron (REGN) stock trades up, here is whyShares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-quarter 2026 revenue to $5.1 billion, alongside a 70% rise in non-GAAP diluted ea
CATALYSTYahoo • 1d ago
EssilorLuxottica Stock And Eurozone Healthcare Giants Worth Watching NowEurozone growth just cooled to 0.4% in Q3, yet still beat forecasts, and that mix of resilience and slowdown is quietly reshaping where money could flow next. Some businesses may benefit if investors rethink how far the
CATALYSTYahoo • 1d ago
Regeneron Bolts 13% Higher, Breaking Out To A Two-Year High On Dupixent DominanceRegeneron stock jumped to a two-year high Friday after its Sanofi-partnered inflammation giant, Dupixent, handily beat expectations.
MARKET WIREYahoo • 1d ago
Regeneron Pharmaceuticals, Inc. Q3 2026 Earnings Call SummaryMoby summary of Regeneron Pharmaceuticals, Inc.'s Q3 2026 earnings call
CATALYSTYahoo • 1d ago
Sanofi Q3 Earnings Call HighlightsSanofi (NASDAQ:SNY) reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. The company also rais
CATALYSTYahoo • 1d ago
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings CallRegeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performan
RISK WATCHYahoo • 1d ago
European Equities Traded in the US as American Depositary Receipts Fall in Friday TradingEuropean equities traded in the US as American depositary receipts were down 0.59% to 1,896.05 on th
CATALYSTYahoo • 1d ago
Regeneron Soars 12% on Dupixent-Fueled Q3 Beat: “One of Our Strongest Years Ever”Key TakeawaysRegeneron shares jumped 12% after third-quarter revenue rose 36% to $5. 1 billion.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live SNY Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
SNY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.81%📐 HORIZONTAL RANGE
2026-10-30O $44.82H $45.30L $44.23C $44.34VOL 15.10M
RES: $46.88SUP: $38.77SMA50: $42.21SMA200: $44.33
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SNY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. -1.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SNY today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SNY. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SNY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
SNY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SNY stock moving today?
Why SNY Stock surged +2.11% Today — RQD Quant Desk Flash. Solid 41% profit margin (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.